Pharmacogenomics of nicotinic acid with laropiprant in Hong Kong Chinese patients with dyslipidemia.

Trial Profile

Pharmacogenomics of nicotinic acid with laropiprant in Hong Kong Chinese patients with dyslipidemia.

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Apr 2016

At a glance

  • Drugs Niacin/laropiprant (Primary)
  • Indications Dyslipidaemias; Hypercholesterolaemia
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 27 Apr 2016 Status changed from recruiting to completed.
    • 13 Apr 2012 Status changed from not yet recruiting to recruiting as reported by Chinese Clinical Trial Register record.
    • 21 Oct 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top